At the Heart of the Statin Benefit**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by LaRosa, John C.
EA
J
B
A
r
l
i
p
s
t
e
s
i
i
a
b
d
h
e
t
a
t
a
r
d
d
l
r
i
B
b
s
e
b
w
S
w
a
i
m
v
A
a
h
Journal of the American College of Cardiology Vol. 46, No. 10, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
Pa
a
t
n
n
s
s
i
i
c
m
w
n
c
e
d
m
p
c
o
h
o
t
e
t
p
i
fi
t
e
b
s
R
C
B
R
1
2
3
4
5
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.032DITORIAL COMMENT
t the Heart of the Statin Benefit*
ohn C. LaRosa, MD
rooklyn, New York
lmost since they were first introduced, statin drugs have been
ecognized to have effects beyond their potent low-density
ipoprotein (LDL)-lowering abilities. These “pleitropic” effects
nclude anti-inflammatory, vascular, and immune-altering
roperties (1). Their existence has led to suggestions that
tatins might be useful in other diseases, ranging from demen-
ia to autoimmune disorders. They have been invoked to
xplain the unexpectedly early reduction in coronary events in
tatin clinical trials, contrary to the later appearance of benefits
n non-statin LDL-lowering trials. They also have been
mplicated in the strong benefit of statin therapy in preventing
therothrombotic strokes, even though cholesterol levels are, at
est, weak predictors of stroke in observational studies. Evi-
ence of the prominent role of inflammation in atherogenesis
as grown apace with the evidence for the anti-inflammatory
ffects of statins. Perhaps as a result, this property has received
he most attention as one of potential clinical significance.
See page 1855
On the other hand, it has been evident for some time that
verage achieved LDL cholesterol levels in placebo and
reatment groups in various statin trials, when plotted
gainst coronary event rates, depict a remarkably linear
elationship. In other words, the results of studies in
ifferent populations (all with stable, not acute coronary
isease), using different statins, at different times, reveal a
inear relationship that fully accounts for the decline in event
ates, without the need to invoke other mechanisms (2).
The “meta-regression” study by Robinson et al. (3) in this
ssue of the Journal refines and extends these observations.
y demonstrating that LDL lowering in non-statin trials
ears the same relationship to event rates as is found in
tatin trials, this analysis adds strong support to the hypoth-
sis that LDL decline is sufficient to explain the observed
enefits without invoking pleitropic effects.
The clinical trials selected for comparison in this analysis
ere all performed in patients with stable coronary disease.
tatin trials involving patients with acute coronary syndromes
ere not included. As a result it is not possible to say whether
nti-inflammatory pleitropic effects might play a more prom-
nent role in patients with acute coronary syndromes, in whom
ore active and inflamed plaque might be present.
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ccounted for primarily by LDL cholesterol reduction,
lthough the absence of stroke end points in non-statin
rials limits this conclusion.
How should these findings shape our thinking? First,
one of these results imply that pleitropic effects are
onexistent. A wealth of laboratory and translational re-
earch exists describing and confirming these effects of
tatin. In some cases, these effects appear to be wholly
ndependent of any changes in circulating lipid fractions.What
s at issue in not the existence of pleitropic effects but their
linical significance in the prevention of vascular events. In
any ways, this situation is comparable with that of estrogen,
here many well-described benefits on vascular function have
ot translated into clinical benefits in trials (4,5).
The analysis by Robinson et al. (3) strongly supports the
oncept that declines in coronary and probably cerebrovascular
vents in patients with stable atherosclerosis result largely from
eclines in LDL levels. It does not appear, moreover, that the
eans by which LDL is lowered is of significant.
Pleitropic effects are of great scientific interest and may
oint to the mechanisms of statin benefits in disorders
ompletely unrelated to circulating lipids. However, the burden
f proof that they are of clinical consequence in atherosclerosis
as not been met. At this point, the benefits of statins and
ther lipid-altering regimens appear to be operating chiefly
hrough LDL lowering. As a result, agents that can most
ffectively and safely achieve the lowest LDLs are likely to be
he most useful in preventing recurring coronary events.
Whether the same might be said for raising high-density lipid
rotein, lowering triglyceride, diminishing inflammation, or alter-
ng vascular dysfunction independent of LDL lowering is not yet
rmly established.Whilewe look for other interventions to extend
he reductions in the catastrophic results of atherosclerosis, how-
ver, we should not fail to apply the one intervention that has now
een proven beyond a reasonable doubt, i.e., aggressive and
ustained lowering of LDL cholesterol.
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